KIBRA interacts with discoidin domain receptor 1 to modulate collagen-induced signalling  by Hilton, Heidi N. et al.
Available online at www.sciencedirect.com
a 1783 (2008) 383–393
www.elsevier.com/locate/bbamcrBiochimica et Biophysica ActKIBRA interacts with discoidin domain receptor 1 to modulate
collagen-induced signalling
Heidi N. Hilton a, Prudence M. Stanford a, Jessica Harris a,1, Samantha R. Oakes a,
Warren Kaplan b, Roger J. Daly c, Christopher J. Ormandy a,⁎
a Development Group, Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia
b Peter Wills Bioinformatics Centre, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia
c Signal Transduction Group, Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW, 2010, Australia
Received 5 July 2007; received in revised form 30 November 2007; accepted 3 December 2007
Available online 9 January 2008Abstract
Mammary gland development is coupled to reproductive events by hormonal cues of ovarian and pituitary origin, which activate a genomic
regulatory network. Identification of the components and regulatory links that comprise this network will provide the basis for defining the network's
dynamic response during normal development and its perturbation during breast carcinogenesis. In this study KIBRA was identified as a transcript
showing decreased expression associated with failed mammary gland development in Prlr knockout mammary epithelium. It is strongly up-regulated
during pregnancy, falls during lactation and is again up-regulated during involution of the gland at weaning. A bioinformatic approachwas undertaken to
identify potential binding partners which interact with theWWdomains of KIBRA.We show that KIBRA binds to aWWdomain binding motif, PPxY,
in the tyrosine kinase receptor DDR1, and dissociates upon treatment with the DDR1 ligands collagen type I or IV. In addition we show that KIBRA and
DDR1 also interact with PKCz to form a trimeric complex. Finally, overexpression and knockdown studies demonstrate that KIBRA promotes the
collagen-stimulated activation of theMAPK cascade. ThusKIBRAmay play a role in how the reproductive state influences themammary epithelial cell
to respond to changing cell-context information, such as experienced during the tissue remodeling events of mammary gland development.
© 2007 Elsevier B.V. All rights reserved.Keywords: Mammary; Progesterone; Cell matrix; PKCζ, ERK MAPK1. Introduction
The mammary gland reaches its full state of development as a
result of hormonal cues that coordinate puberty, pregnancy and
parturition with the developmental events that build and activate
the mammary secretory epithelium [1–3]. Estrogen and growth
hormone cause the formation of the mammary ductal network
during pubertal development, and progesterone causes side bran-
ches to formwith each estrous or menstrual cycle [4–6]. Prolactin
and progesterone stimulate the development of the lobuloalveoli
during pregnancy [4–7]. Lactation is initiated following parturi-⁎ Corresponding author. Cancer Research Program, Garvan Institute of
Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
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doi:10.1016/j.bbamcr.2007.12.007tion by the combined decrease in progesterone levels and increase
in prolactin levels. Lactation is maintained by prolactin until
weaning causes a combination of reduced nervous stimulation of
prolactin release and engorgement of the ductal network, trig-
gering the apoptotic involution of the lobuloalveoli [3]. Devel-
opmental events elicited by these hormones initiate transcriptional
changes that are programmed by an inheritable and robust ge-
nomic regulatory network [8].
During carcinogenesis the genomic regulatory network is
perturbed and tumour growth occurs. Defining these regulatory
networks and the signalling systems that control them offers an
insight into the biology of organ development, provides the
foundation to understand how the process is dysregulated during
carcinogenesis, and may identify new therapeutic targets. To
explore the genomic regulatory network operating during preg-
nancy in the mammary gland, we transcript profiled prolactin
receptor knockout (Prlr−/−) and wild type (Prlr+/+) mammary
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transcript with altered expression in Prlr+/+ mammary epithelial
transplants compared to Prlr−/− transplants during early preg-
nancy, with expression confined to the epithelial cells.
KIBRA was originally identified from a yeast two-hybrid
screen of a human brain cDNA library as a protein which
interacts with the postsynaptic protein Dendrin, and contains two
N-terminal WW domains, and a C2 domain [10]. The WW
domain is a protein interaction module that recognises specific
proline-containing peptide sequences [11]. They are found in a
variety of proteins involved in diverse cellular processes in-
cluding protein degradation, transcription regulation and differ-
entiation, and are also associated with a number of human
diseases including muscular dystrophy, Alzheimer's disease and
cancer [12]. The C2 domain is a conserved membrane-targeting
motif that mediates an array of intracellular processes, the majo-
rity of which involve signal transduction and membrane traf-
ficking [13]. The presence of these domains suggested a scaffold
protein role for KIBRA in the formation of a signalling complex.
To date, the functional role of KIBRA has been implicated in
synaptic signalling and memory formation[14,15], and as a tran-
sactivator of the estrogen receptor in human breast cancer cells
with a potential role in transport along the microtubules, via its
interaction with dynein light chain 1 (DLC1) [16].
To further understand how hormonal regulation of KIBRA
could influence mammary gland development, we sought to
examine the regulation of KIBRA, identify its binding partners
and define a signalling pathway endpoint that responds to mani-
pulation of KIBRA expression. Following this approach we have
identified Discoidin Domain Receptor 1 (DDR1) as a novel
binding partner ofKIBRA and show that this occurs in a collagen-
regulated manner. Furthermore, we demonstrate that KIBRA is
involved in the collagen-stimulated activation of the MAPK
cascade.
2. Methods
2.1. Mammary epithelial transplantation and transcript profiling
Mammary epithelial transplants of Prlrwildtype (Prlr+/+) and knockout (Prlr−/−)
epithelium and transcript profiling was performed as previously described by
Harris et al. [9].
2.2. Quantitative PCR
1 μg RNAwas reverse transcribed using AMV reverse transcriptase in a 20 μL
reaction (Promega, Madison, WI). PCR reactions were performed in a LightCycler
(Roche Diagnostics, Mannheim, Germany) using 1 μL of the cDNA (diluted 1:2),
5 pmol of primers and the FastStart DNAmaster SYBRGreen I enzymemix (Roche)
in a 10 μL reaction volume. Relative quantification was performed by RelQuant
software (Roche). Absolute quantification was performed by comparison to a
standard curve constructed from serial dilutions of a PCR product purified using
QIAquick Gel Extraction Kit (Qiagen, Valencia, CA) and analysed using the Second
Derivative Maximum method (Roche). Data was normalised to expression of the
housekeeping genes β-actin or aminolevulinic acid synthase 1 (ALAS1) [17,18].
2.3. Bioinformatics to identify proteins
Build 33 of the human proteome, containing 37,490 sequences, was downloaded
from the NCBI (http://www.ncbi.nlm.nih.gov) and the protein regular expressionprogram “Preg” [19] was used to identify all sequences in the proteome with the
PPxYandRxPPxYmotifs (where P is proline, R is arginine,Yis tyrosine and x is any
amino acid). The GI accession numbers from the matched sequences were used to
extract annotations from the 15 June 2003 build of the Affymetrix HGU-133A
annotation file. The annotations were then extended by searching batch SOURCE
[20] with the LocusLink identity numbers derived from the matched Affymetrix
HGU-133A annotations. Protein expression in the mammary gland was determined
from the NCBI Unigene database (http://www.ncbi.nlm.nih.gov/unigene).
2.4. Antibody preparation
Anti-KIBRA antiserum was prepared in rabbit (Invitrogen Life Technologies,
Carlsbad, CA) using the synthetic peptide sequence, SAQERYRLEEPGTEGKQ,
derived from the human KIBRA central portion, conjugated to keyhole limpet
haemocyanin (KLH). The KIBRA IgG polyclonal antibody was purified on a
peptide affinity column.
2.5. Immunohistochemistry
4 μm tissue sections were mounted on Superfrost Plus adhesion slides (Lomb
Scientific, Sydney, Australia) and heated in a convection oven at 75 °C for 2 h to
promote adherence. Sectionswere de-waxed and re-hydrated according to standard
protocols. Antigen retrieval was performed using citrate EDTA buffer boiled under
pressure (human cells) or Proteinase K enzymatic digestion (human and mouse
tissue). Endogenous peroxidase activity was inhibited with 3% H2O2. Sections
were incubated with the anti-KIBRA primary antibody for 60 min (1:200, human
tissue and cells) or 30 min (1:150, mouse tissue) and bound antibody was detected
using LINK/LABEL and 3, 3′-diaminobenzidine Plus as substrate. With each run,
diluent and rabbit IgG isotype control were the negative technical controls.
Counterstaining was performed with haematoxylin and 1% acid alcohol. Cell lines
were processed at the same time to enable comparison of signal strength. All
immunohistochemistry reagents were obtained from DAKO Corporation (Carpin-
teria, CA) unless otherwise specified.
2.6. Plasmids
The human KIBRA cDNAwas cloned from HEK-293 cells by PCR into the
Gateway entry vector pDONR221 (Invitrogen) using Forward Primer 5′-GGGG
ACA AGT TTG TAC AAA AAA GCA GGC TGG AAG ATG CCC CGG CCG
GAG C-3′ and Reverse Primer 5′-GGGG AC CAC TTT GTA CAA GAA AGC
TGG GTA GAC GTC ATC TGC AGA GAG AGC TGG-3′. Similarly, two
overlapping fragments (WW and C2) of the KIBRA cDNA were cloned into
pDONR221 by PCR. Fragment 1, containing the twoWWdomains, was amplified
using the Forward Primer described above, and 5′-GGGG AC CAC TTT GTA
CAAGAAAGCTGGGTATTACGATACGGCGGC TGAGACACAGG-3′.
Fragment 2, containing the C2 domain, was amplified using 5′-GGGGACAAGT
TTG TAC AAA AAA GCA GGC TTC ACC ATG GAG AGG GAC CGG CTG
ATC CTT ATC-3′ and the Reverse Primer described above. The KIBRA cDNA
and WW and C2 fragments were then cloned into the mammalian Gateway
expression vector pcDNA-DEST40 (CMV/C-terminal V5-6xHis) by recombina-
tion (Invitrogen). The pRK5-DDR1b expression plasmid was kindly provided by
Dr A. Ullrich, Max Planck Institute, Germany. The pRcCMV-PKCζ expression
plasmid was kindly provided by Dr T. Biden, Garvan Institute, Australia. Human
KIBRA cDNA was also subcloned into the NotI site of the untagged expression
plasmid pcDNA3.1(+) via the pGEM-T Easy Vector System 1 (Promega) using
primers KIBRA5′Forward (GG AAG ATG CCC CGG CCG GAG C) and
KIBRA3′Reverse (C TTT TCT GGC GAT TAG ACG TCA TCT GC). For
knockdown of mKibra in HC11 cells an siRNA duplex was designed using the
algorithm as described in Reynolds et al, 2004 [21]. Double-stranded RNA
oligonucleotides against the target sequence GCUUCACUGACCUCUAUUA
were synthesised by Dharmacon Research Inc. (Layfayette, CO). For knockdown
of hKibra in MCF-10A cells siRNA duplexes were purchased from Dharmacon.
2.7. Site-directed Mutagenesis
The DDR1 mutants were constructed by site-directed mutagenesis with the
pRK5-DDR1b plasmid as a template using the QuikChange® II Site-Directed
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each mutant, two complementary synthetic oligonucleotides were designed of
which one is indicated: AAPY mutant, 5′-GGT CCT AGA GAG GCA GCC
CCG TAC CAG GAG-3′, AAAA mutant, 5′-GA GAG GCA GCC GCG GCC
CAG GAG CCC CGG-3′ and PPPF mutant, 5′-GGT CCT AGA GAG CCA
CCC CCG TTC CAG GAG-3′. The mutated plasmids were transformed into
Escherichia coli XL1 Blue Supercompetent cells (Stratagene), and the mutants
were verified by sequencing of the plasmid DNA.2.8. Cell culture and transient transfections
HEK-293 cells were maintained in Minimum Essential Media (MEM) sup-
plementedwith 10% foetal bovine serum (FBS) and 0.5 g of sodiumbicarbonate per
litre. Semiconfluent HEK-293 cells were transiently transfected using Fugene
reagent (Roche Applied Science) according to the manufacturer's instructions.
After 48 h cells were harvested for immunoprecipitation experiments. T47D human
breast cancer cells were cultured in RPMI 1640 medium supplemented with 10%
FBS and 10μg/mL insulin. HC11murinemammary cells weremaintained inRPMI
1640 medium supplemented with 10% heat inactivated FBS, 5 μg/mL insulin and
10 ng/mL epidermal growth factor. Progesterone stimulation experiments involved
treating T47D cells with 10 nM ORG2058 (16a-ethoxy-21-hydroxy-19-norpregn-
4-en-3,20-dione), which was obtained from Amersham Biosciences, Australia, or
100 nM RU486 [17 beta-hydroxy-11- beta-(4-methylaminophenyl)-17-alpha-(1-
propynyl)-etra-4,9-diene-3-one], which was generously provided by Dr J-P
Raynaud of Roussel-Uclaf, Romainville, France. MCF-10A cells were maintained
as previously described [22]. For collagen treatment, HEK-293 andMCF-10A cells
were serum starved overnight, then treated with 10 μg/mL of collagen type IV
(human placenta; Sigma, Castle Hill, NSW, Australia) or collagen type I (rat tail;
Sigma) for 90 min, unless otherwise specified.
2.9. Immunofluorescence microscopy
Subcellular localisation of KIBRA was assessed using T47D breast cancer
cells, and HeLa cells transfected with KIBRApcDNA3.1. Cells were plated onto
chamber slides, fixed in 4% paraformaldehyde/PBS, permeablized in 0.2% Triton
X-100, and blocked with 1% BSA in PBS. Following incubation with the primary
KIBRA antibody (1:100), the cells were stained using rabbit Cy2- or Cy3-labelled
secondary antibodies (Jackson ImmunoResearch Laboratories, Pennsylvania,
USA), FITC-phalloidin (Sigma) as an actin counterstain, and TOPRO-3 (Mole-
cular Probes OR, USA) as a DNA counterstain. Controls included KIBRA peptide
block and secondary antibody only. Cells were visualised using confocal micro-
scopy (Leica Microsystems, Sydney, Australia).
2.10. Immunoprecipitation and Western Blot Analysis
Protein samples were prepared from cell lines lysed in normal lysis buffer
(50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM
MgCl2, 1mMEDTA, 10mMpyrophosphate, 100mMNaF) containing protease and
phosphatase inhibitor cocktail tablets (Roche). For analysis of KIBRA phosphoryla-
tion T47D lysates were incubated with lambda protein phosphatase (New England
Biolabs) according to the manufacturer's instructions. For immunoprecipitation
experiments, 1 mg of protein from cell lysates was incubated with antibodies
overnight at 4 °C. Protein-G sepharose beads were added to the lysates and incubated
for 1 h at 4 °C. The resulting immunoprecipitates were washed four times with lysis
buffer and 1MNaCl, and resuspended inNuPAGE sample buffer and reducing agent
(Invitrogen). Immunoprecipitates were separated onNuPAGE 4–12%acrylamide
gels (Invitrogen) and transferred to a PVDFmembrane. Blots were incubatedwith
the following primary antibodies overnight at 4 °C:α-KIBRA,α-V5 (Invitrogen),
α-phosphotyrosine (4G10) (Upstate Biotechnology, Lake Placid, NY), α-DDR1
(C-20) and α-nPKCζ (C-20) (Santa Cruz Biotech), α-phosphorylated and α-total
p44/42 MAP kinase (Cell Signaling Technology), and α-βactin (Sigma). Horse-
radish peroxidase-linked secondary antibodies were used to detect a signal by
enhanced chemiluminescent detection.
2.11. Densitometry
This was performed using IP Lab Gel software (Signal Analytics Corp) and
statistical analyses were performed using StatView 4.5.Fig. 1. KIBRA transcript levels in mouse tissue and human breast cancer cell
lines. A. Number of mKibra transcripts in each of the Prlr+/+ (W) and Prlr−/− (K)
mammary epithelial transplants and Prlr+/+ fat pads cleared of epithelium (C)
during days 2, 4 and 6 of pregnancy. B. Transcript levels of mKibra in wild-type
mammary glands at different stages of development. C. hKIBRA transcript
levels in human mammary epithelial cells and breast cancer cell lines. Gene
expression levels of the prolactin receptor (PRLR), estrogen receptor (ER) and
the progesterone receptor (PgR) in each cell line is indicated. Transcript levels
were determined by absolute quantitative PCR. Error bars represent the range
from duplicate measurements.
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3.1. Identification of decreased expression of KIBRA in a mouse
model of failed mammary gland proliferation and lobuloalveolar
development
Prlr+/+ and Prlr−/− mammary epithelia were transplanted into
the clearedmammary fat pads of 4 week old Rag1−/− animals.We
transcript profiled the Prlr+/+ and Prlr−/− mammary epithelial
transplants during early pregnancy to identify gene expression
changes that occur in mammary glands with failed alveolar mor-150 kDa
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G IHphogenesis as a result of the loss of Prlr. We chose early time
points of pregnancy to overcome the reduced epithelial cell
numbers observed in Prlr−/− mammary glands [9]. To exclude
gene expression contributed by the fat pad we also transcript
profiled Rag1−/− mammary fat pads cleared of endogenous
epithelium. This combined analysis identified a number of genes
known to be important for mammary development as decreasing
in the Prlr−/− epithelium during pregnancy [9]. Here we report
the identification of the murine EST, AI850846, as a mammary
epithelium specific transcript that was decreased in Prlr−/−
mammary epithelium compared to Prlr+/+ mammary epithelium.
Sequence database searches identified that AI850846 corre-
sponded to a proteinwhich has since been namedKIBRA/WWC1
(GenBank accession no. NM_170779 [mouse]; NM_015238
[human]), and the mouse and human orthologues share 91%
amino acid identity. We therefore refer to the mouse and human
gene products identified in this study as mKibra and hKIBRA,
respectively.
Changes in the MAS 4.0 Average Difference for mKibra from
theMGU74AAffymetrixGeneChipswere confirmed by absolute
quantitative PCR. Each sample for the transcript profiling and the
quantitative PCR consisted of RNA pooled from 4 to 6 animals.
mKibra mRNA levels were lower in the Prlr−/− mammary epi-
thelial transplants than the Prlr+/+ mammary epithelial transplants
at days two, four and six of pregnancy (Fig. 1A ). mKibra mRNA
levels were undetectable above background in the Prlr+/+ fat pads
cleared of epithelium, confirming KIBRA expression is specific
to the mammary epithelium (Fig. 1A).
3.2. KIBRA expression in mammary gland and breast
mKibra mRNA levels were examined in mammary glands
from wild-type animals at different stages of development by
quantitative RT-PCR. mKibra mRNAwas detected at all stages of
development in the mammary gland (Fig. 1B). mKibra mRNA in
the mammary gland increased duringmid pregnancy (day 12) to aFig. 2. KIBRA protein expression in mouse and human cells. A. Validation of anti-
KIBRA antibody as shown by Western blot. Lysates (20 μg) were loaded, as
labelled, of MCF-10A (normal human mammary epithelial cell line), BT20 and
T47D +/− lambda protein phosphatase (human breast cancer cell lines), HC11 +/−
KIBRA siRNA (normal murine mammary epithelial cell line). Lysate of HEK-293
transfected with KIBRApcDNA3.1 is shown at a shorter exposure due to over-
expression. Lysates were blotted with the anti-KIBRA antibody, which detects a
band under the 150 kDamarker for both human andmouse samples. B. Localisation
of KIBRA as examined by immunofluorescence. T47D breast cancer cells were
stained with anti-KIBRA antibody, shown in green. Actin is shown in red, and the
nucleus is shown in blue.White arrows indicate where KIBRA co-stains with the
nucleus. C. Immunofluorescence ofHeLa cells transfectedwithKIBRApcDNA3.1.
Cells were fixed, permeabilised and stained with anti-KIBRA antibody, shown in
green. The white arrow indicates staining of membrane ruffles. D. KIBRA protein
expression in BT474 cells as examined by IHC. E. BT20 cells F. MDA-MB-157
cells G. Normal human breast tissue. Open arrow indicates positive KIBRA
staining of luminal epithelial cells. Filled arrow shows negative KIBRA staining of
surrounding myoepithelial cells H. and I. High grade IDC. Open arrows indicate
KIBRA staining at membranous regions. Filled arrow indicates cytoplasmic
staining of KIBRA. J–O. IHC analysis of KIBRA protein expression in mouse
mammary tissue throughout development. (J. 12weekvirginK. 2.5 days post coitus
L. 6.5 days post coitus M. 12.5 days post coitus N. 18.5 days post coitus O. 1 day
post partum.) Scale bars on all images represent 10 μM.
Fig. 3. KIBRA expression is strongly up-regulated by progestin treatment.
A. Western blot of time course showing KIBRA protein expression in T47Ds
following treatment with 10 nM ORG2058 for between 4 h and 5 days. B. Data
generated from densitometry of 5 separateWestern blots (each bar is mean±SE).
C. KIBRA protein levels following 24 h 10 nM ORG2058 treatment alone, and
24 h co-treatment with 10 nM ORG2058 and 100 nM RU486.
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followed by a decrease at later time points (day 9). At involution
of the mammary gland (day 1) mKibra mRNA levels increased
again to levels observed at day 18 of pregnancy. hKIBRA tran-
script levels were examined in a panel of primary breast cancer
cell lines, aswell as normal and immortal basal epithelial cell lines
(HMEC) by quantitative RT-PCR. KIBRA expression was low in
the normalHMEC cell lines which have a finite lifespan, higher in
the immortalmammary cell lines, and showed variable expression
in the breast cancer cell lines (Fig. 1C). The expression did not
appear to correlate with the expression of the prolactin receptor or
steroid hormone receptors (Fig. 1C) [23,24].
In order to analysemKibra and hKIBRAat the protein level we
generated an affinity purified anti-KIBRA antibody. Fig. 2A
shows a Western blot of KIBRA expression in various mammary
cell lines, bothmouse and human, using our KIBRA antibody.We
observed specific bands of the KIBRA protein running below the
150 kDa size marker and often as a doublet. When T47D breast
cancer cell lysates were treated with lambda protein phosphatase
only the lower band of the doublet remained indicating that the
upper band is due to post-translational phosphorylation (Fig. 2A).
Whether KIBRA is present predominantly as the phosphorylated
form or non-phosphorylated form depends on the cell line, for
example in normal murine mammary epithelial HC11 cells,
mKibra is observed as the phosphorylated form only. KIBRA
shows a predominantly cytoplasmic localisation [10], however a
significant amount can also be seen in the nucleus of a subset of
cells, as shown by immunofluorescence microscopy of endogen-
ous levels of KIBRA in T47D cells (Fig. 2B). KIBRA has pre-
viously been reported to have a nuclear localisation signal in the
protein sequence [16], and this interesting expression pattern
suggests a potential nuclear function of KIBRA. The cellular
distribution ofKIBRA in transfectedHeLa cells is cytoplasmic, as
well as showing staining at membranous regions, particularly in
membrane ruffle structures (Fig. 2C). The KIBRA transcript
levels measured in a panel of breast cancer cell lines by quan-
titative RT-PCR (Fig. 1C) were reproduced by immuohistochem-
ical signal strength as shown byBT474 cells (Fig. 2D), BT20 cells
(Fig. 2E) and MDA-MB-157 cells (Fig. 2F). In human breast
tissue, KIBRA protein is present in the luminal epithelium
surrounding the ducts in the normal breast, but is not expressed in
the myoepithelium, stromal adipocytes or fibroblasts (Fig. 2G).
KIBRA protein was also detected in cancerous tissue and showed
heterogeneous expression in both the preinvasive (data not
shown) and invasive ductal carcinoma (IDC; Fig. 2H and I).
Shown also is the expression of KIBRA protein in mouse mam-
mary tissue throughout development (Fig. 2J–O). It is observed as
surrounding the alveoli structures and is predominantly cyto-
plasmic, as seen at time points of 18. 5 days post coitus (Fig. 2N)
and 1 day post partum (Fig. 2O), which corresponds to mKIBRA
mRNA levels shown in Fig. 1B.
3.3. Effect of hormonal stimulation on KIBRA gene expression
We identified KIBRA as being a gene showing decreased
expression in Prlr−/− mammary epithelium and increased ex-
pression by MAS analysis in two SCp2 cell experimentsfollowing treatment with prolactin, as outlined in Harris et al.
(2006) (data not shown). We also investigated the effect of other
hormones that are required for alveolar morphogenesis. When
we treated T47D cells, a progesterone-responsive human breast
cancer cell line, with the synthetic progestin ORG2058, we
observed a strong up-regulation of KIBRA expression. Fig. 3A
shows levels of KIBRA protein expression following ORG2058
treatment over a five day time course. Up-regulation of KIBRA
expression is observed from 8 h of treatment and was main-
tained to at least 5 days. This progestin-induced up-regulation of
KIBRA was also observed in BT474 cells, which is another
PgR-positive human breast cancer cell line (data not shown).
Fig. 3B depicts the relative increase in KIBRA expression from
densitometry analysis of 5 experiments. We also co-treated the
cells with ORG2058 and the progestin antagonist RU486 for
24 h, and this inhibited the increase in KIBRA expression,
indicating this up-regulation occurs in a PgR-specific manner
(Fig. 3C). Together these experiments demonstrate that KIBRA
388 H.N. Hilton et al. / Biochimica et Biophysica Acta 1783 (2008) 383–393expression is regulated by two hormones that drive alveolar
morphogenesis.
3.4. Identification of KIBRA interacting partners
To gain an understanding of the function of KIBRA in the
mammary gland we undertook a bioinformatic approach to iden-
tify potentialKIBRA interacting proteins.WWdomains recognise
specific proline-containing peptides, in particular the sequence
motif, PPxY (where P is proline, Y is tyrosine, and x is any amino
acid) [25]. We mined the human proteome for proteins that con-
tained the PPxY motif using the protein regular expression
program “Preg” [19]. This list was further refined by selecting
proteins that contained the motif RxPPxY (where R is arginine),
the preferred putative consensus recognition motif for KIBRA
[10], and were expressed in the mammary gland (Table 1). From
these candidates we selected DDR1, a collagen activated tyrosine
kinase receptor, and ErbB3, a heregulin co-receptor due to their
involvement in signalling pathways, as KIBRAwas proposed to
act as a potential signalling scaffold due to the presence of theWW
and C2 domains.
3.5. KIBRA interacts with DDR1 in a collagen-regulated manner
We co-expressed full-length cDNAs of KIBRA and either
ErbB3 or DDR1 in HEK-293 cells, and attempted co-immuno-
preciptation with KIBRA. No signal was observed when weTable 1
List of candidate KIBRA interacting proteins containing RxPPxY motif and are exp
Sequence derived from Gene title
NM_003035 TAL1 (SCL) interrupting locus
NM_001447 FAT tumor suppressor homolog 2 (Drosophila)
NM_023038 A disintegrin and metalloproteinase domain 19
NM_005401 Protein tyrosine phosphatase, non-receptor type 14
NM_005529 Heparan sulfate proteoglycan 2
NM_007039 Protein tyrosine phosphatase, non-receptor type 21
NM_007286 Synaptopodin
NM_014945 Actin binding LIM protein family member 3
NM_006720 Actin binding LIM protein 1
NM_004393 Dystroglycan 1
NM_003494 Dysferlin, limb girdle muscular dystrophy 2B
NM_001954 Discoidin domain receptor 1
NM_001982 v-erb-b2 erythroblastic leukemia viral oncogene homolog
NM_005157 v-abl Abelson murine leukemia viral oncogene homolog 1
NM_005642 TAF7 RNA polymerase II
NM_005933 Myeloid/lymphoid or mixed-lineage leukemia
NM_014757 Mastermind-like 1 (Drosophila)
NM_012245 SKI-interacting protein
NM_012406 PR domain containing 4
NM_014345 Zinc finger protein 318
NM_012091 Adenosine deaminase, tRNA-specific 1
NM_133330 Wolf–Hirschhorn syndrome candidate 1
NM_022902 Solute carrier family 30 (zinc transporter)
NM_003730 Ribonuclease 6 precursor
NM_018641 Chondroitin 4-O-sulfotransferase 2
NM_014262 Leprecan-like 2 protein
NM_014427 Copine VII
NM_001649 Apical protein-like (Xenopus laevis)
NM_013423 Rho GTPase activating protein 6reblotted with antibodies against ErbB3 (data not shown), how-
ever we did observe co-immunoprecipitation of KIBRA and
DDR1.Whenwe co-expressed KIBRA andDDR1 and treated the
cells with collagen type IV, a ligand of DDR1, we observed that
more DDR1 co-immunoprecipated with KIBRA in the absence of
collagen than in the presence of this ligand (Fig. 4A ). Using a
second DDR1 ligand, collagen type I, we also observed that less
DDR1 co-immunoprecipitated in the presence of this ligand
(Fig. 4B). We confirmed that this interaction was collagen-
regulated by performing the reciprocal immunoprecipitation,
where we observed KIBRA immunoprecipitation with DDR1
antibodies, but not in the presence of collagen IV (Fig. 4C).
Furthermore, we performed a kinetic study of DDR1 activation
over a 4 h time course and observed a gradual dissociation of
KIBRA from DDR1 over time (Fig. 4D). Exposure to collagen
causes tyrosine phosphorylation of DDR1 [26], and particularly
interesting is the observation that the time point at which DDR1 is
first shown to be tyrosine phosphorylated upon collagen treatment
(t=1 h), is also the first time point at which less DDR1 is observed
to co-immunoprecipitate with KIBRA (Fig. 4D). This displace-
ment also occurred in a dose-responsive manner upon collagen
treatment (Fig. 4E). Although the sensitivity of the KIBRA anti-
body precluded detection of an association between endogenous
KIBRA and endogenous DDR1, we could detect recruitment of
exogenous KIBRA to endogenous DDR1 (Fig. 4G). Together,
these data show that KIBRA interacts with DDR1 and that this
interaction is regulated by collagens that bind and activate DDR1.ressed in mammary gland
Gene symbol Function RxPPxY sequence
SIL Cell proliferation RQPPAY
FAT2 Cell proliferation and adhesion RVPPNY
ADAM19 Cell–cell and cell–matrix interactions RPPPDY
PTPN14 Signal transduction RPPPPY
HSPG2 Basement membrane molecule RCPPGY
PTPN21 Signal transduction RPPPPY
SYNPO Cytoskeletal molecule RSPPSY
ABLIM3 Cytoskeletal molecule RKPPIY
ABLIM1 Cytoskeletal molecule RKPPIY
DAG1 Muscle contraction RSPPPY
DYSF Muscle contraction RPPPHY
DDR1 Protein tyrosine kinase receptor REPPPY
3 ERBB3 Protein tyrosine kinase receptor RDPPRY
ABL1 Protein tyrosine kinase activity REPPFY
TAF7 RNA polymerase II transcription factor RLPPEY
MLL RNA polymerase II transcription factor RQPPEY
MAML1 Transcriptional co-activator RPPPQY
SKIIP Transcription co-activator REPPPY
PRDM4 Transcription factor RPPPQY
ZNF318 RNA binding RIPPNY
ADAT1 RNA binding and processing RNPPDY
WHSC1 Embryogenesis and morphogenesis RKPPPY
SLC30A5 Zinc transporter RLPPEY
RNASE6PL Ribonuclease activity RDPPDY
C4S-2 Transferase activity RFPPSY
LEPREL2 Protein metabolism REPPAY
CPNE7 Lipid metabolism RIPPKY
APXL Sodium channel activity RHPPLY
ARHGAP6 Rho GTPase activator activity RPPPPY
Fig. 4. KIBRA interacts with DDR1 in a collagen-regulated manner. A. KIBRA immunoprecipitates from HEK-293 cells transiently co-transfected with KIBRA and
DDR1b cDNAs and blotted with anti-KIBRA and anti-DDR1 showing that DDR1b co-precipitates with KIBRA. B. Co-immunoprecipitation of KIBRA and DDR1 +/−
collagen type I. C. DDR1 immunopreciptates from transfected HEK-293 cells +/− collagen showing that KIBRA co-precipitates with DDR1 in the absence of collagen
IV. D. Co-immunoprecipitation of KIBRA and DDR1 over a 4 h time course of collagen treatment. Levels of total and phosphorylated DDR1 in whole cell lysates are
shown. E. Co-immunoprecipitation ofKIBRA andDDR1 in response to increasing concentrations of collagen IV. F. Endogenous DDR1 immunoprecipitates fromT47D
cells transiently transfected with KIBRA showing an interaction between KIBRA and endogenous DDR1. NLB=normal lysis buffer control.
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To determine whether the KIBRA-DDR1 interaction was
occurring via the PPxY motif of DDR1, we performed site-
directed mutagenesis on this motif. Three DDR1 mutants were
made where the target motif (PPPY) was mutated to AAAA,
AAPY and PPPF (where A is alanine, P is proline, Y is tyrosine
and F is phenylalanine). Full-length KIBRA was co-expressed
with either wild-type DDR1 (DDR1-wt) or the DDR1 mutants.
Only DDR1-wt, and not DDR1-AAAA,DDR1-AAPYorDDR1-
PPPF, co-immunoprecipitated with KIBRA (Fig. 5A ). Similar
expression in the protein lysates of DDR1-wt and the mutant
constructs is demonstrated in the bottom panel of Fig. 5A. The-
refore, the loss of the two proline residues or the tyrosine residues
in the PPxY sequence abolishes binding of DDR1 to KIBRA,
confirming that integrity of this consensus motif is critical for the
interaction to occur.
PPxY motifs bind to WW domains of their target proteins.
To determine whether the KIBRA and DDR1 interaction was
mediated by the two WW domains of KIBRA, we constructed
two overlapping V5-tagged fusion proteins. One included the
WW domains of KIBRA, and the other included the C2 domain(Fig. 5B). We co-expressed DDR1 with either WW-V5, C2-V5
or full-length KIBRA-V5. When we immunoprecipitated with
the KIBRA antibody, DDR1 was pulled down with full-length
KIBRA-V5 and WW-V5, but not with the C2-V5 fusion protein
(Fig. 5C). These data indicate that KIBRA and DDR1 interact
via a fragment of KIBRA containing the WW domains and the
PPPY motif of DDR1.
3.7. KIBRA interacts with DDR1 and PKCζ in a complex
KIBRA has been reported to interact with protein kinase Cζ
(PKCζ) [14]. We confirmed this by immunoblotting and showed
that endogenous PKCζ co-immunoprecipitates with KIBRA in
HEK-293 cells (Fig. 5C). PKCζ is pulled down with C2-V5
KIBRA, which is in agreement with Buther et al. (2004) who
mapped the KIBRA binding site to a short 44 amino acid fragment
downstream of the C2 domain [14]. We observed that both DDR1
and endogenous PKCζ co-precipitate together with full-length
KIBRA, but not the C2 domain or WW domain fragments of
KIBRA alone, suggesting that KIBRA, DDR1 and PKCζ interact
in a complex.Whenwe co-expressedKIBRA,DDR1 and PKCζ in
HEK−293 cells we observed co-immunoprecipitation of all three
Fig. 5. KIBRA and DDR1 interact via their respective WW domains and PPxY motif. A. KIBRA immunoprecipitates from HEK-293 cells transiently transfected with
DDR1b or DDR1 mutants (AAPY, AAAA or PPPF) and blotted with anti-KIBRA and anti-DDR1. Only wild type DDR1b co-precipitates with KIBRA. B. Schematic
of KIBRA protein showing the WW and C2 fragments and the KIBRA antibody peptide site. C. KIBRA immunoprecipitates from HEK-293 cells transiently co-
transfected with DDR1b and each of WW-V5-6xHIS, C2-V5-6xHIS or KIBRA-V5-6xHIS and blotted with anti-V5 and anti-DDR1. DDR1 co-precipitates with full
length KIBRA and the WW fragment but not with the C2 fragment. Endogenous PKCζ also co-immunoprecipitates with full length KIBRA and the C2 fragment.
D. DDR1 immunoprecipitates from HEK-293 cells (+/− collagen) transiently co-transfected with DDR1, KIBRA and PKCζ. KIBRA and PKCζ co-precipitate with
DDR1 predominantly in the absence of collagen, and only minimal amounts are pulled down following collagen treatment. E. KIBRA immunoprecipitates from HEK-
293 cells transiently transfected with DDR1 and KIBRA over a time-course of collagen treatment. The levels of endogenous PKCζ that are pulled down with KIBRA
remain constant over the time course.
390 H.N. Hilton et al. / Biochimica et Biophysica Acta 1783 (2008) 383–393proteins using DDR1 antibodies (Fig. 5D). The presence of
collagen reduced the amount of KIBRA co-precipitating with
DDR1, and the amount of associated PKCζ decreased in
proportion (Fig. 5D). In addition, collagen treatment has no effect
on theKIBRA-PKCζ interaction.Although the levels ofDDR1 co-
immunoprecipitated with KIBRA decrease over a time course of
collagen treatment, the levels of PKCζ remain the same (Fig.5E).
These data indicate that KIBRA, DDR1 and PKCζ interact in a
tripartite complex, but predominantly in the absence of collagen.
3.8. Modulation of KIBRA expression has downstream effects
on the collagen-stimulated activation of ERK MAPK
Having demonstrated that KIBRA interacts in a complex with
DDR1 and PKCζ, we searched for common downstream targets
of both DDR1 and PKCζ that may provide clues as to the
functional role of KIBRA. We identified the ERK MAPK cas-
cade, a ubiquitous cytoplasmic signalling pathway with a criticalrole in fundamental biological processes such as cell proliferation,
differentiation and apoptosis, as being a downstream target of
both DDR1 and PKCζ. To investigate whether KIBRA may also
be involved in this pathway we transfected HEK-293 cells with
KIBRA (KIBRApcDNA3.1) or vector (pcDNA3.1) and stimu-
lated with collagen type IV. As shown in Fig. 6, KIBRA-trans-
fected cells show increased levels of phospho-ERK when
exposed to collagen, relative to vector-only cells. No changes
were observed in total ERK levels (Fig. 6A). Fig. 6B shows
densitometric analysis of a representative Western blot, revealing
an approximate 3–4 fold increase in levels of phospho-ERK in
cells transfected with KIBRA in the presence of collagen, com-
pared to empty vector controls. To confirm KIBRA is involved in
the collagen-regulated stimulation of theMAPKpathwaywe used
the normal human mammary epithelial cell line, MCF-10A, to
determine whether there was any effect on the activation of this
signal transduction cascadewhen endogenousKIBRAexpression
was knocked down by siRNA. Fig. 6C shows that ERK is
Fig. 6. KIBRA regulates collagen-stimulated ERKMAPK activation. A. Repre-
sentative immunoblots of lysates from HEK-293 cells transiently transfected
with KIBRApcDNA3.1 and pcDNA3.1 and treated +/− collagen for 20 min.
B. Corresponding graph depicting fold increase in ERK phosphorylation.
C. Western blot of lysates from MCF-10A cells transfected with KIBRA siRNA
duplexes and treated +/− collagen for 20 min. D. Corresponding graph depicting
fold increase in ERK phosphorylation as determined by densitometric analysis.
391H.N. Hilton et al. / Biochimica et Biophysica Acta 1783 (2008) 383–393activated upon short-term stimulation with collagen in mock and
RISCfree siRNA controls, but that this activation is suppressed
when KIBRA expression is knocked down using 2 differentsiRNA duplexes. Fig. 6D shows the corresponding densitometric
analysis. These data demonstrate that KIBRAplays a positive role
in the collagen-stimulated activation of the ERKMAPK cascade.
4. Discussion
In this study, we have identified KIBRA as a hormonally-
regulated epithelial-specific mammary gland transcript that
showed decreased expression in the Prlr knockout mammary
epithelium and increased expression in response to Pg. We have
shown that KIBRA interacts in a collagen-regulated manner
with DDR1, a protein known to have an important role in
mammary development [27], and that this interaction occurs via
the PPxY motif of DDR1. Furthermore, we have demonstrated
that KIBRA interacts simultaneously with DDR1 and PKCζ,
and that KIBRA is involved in the collagen-regulated stimula-
tion of the MAPK cascade.
KIBRA expression is epithelial-specific with moderate ex-
pression levels in the mammary gland and high expression in the
kidney and brain. In addition to showing decreased expression in
Prlr−/−mice, KIBRA is markedly up-regulated with progesterone
treatment. It is interesting to note that a number of other genes
were identified in the original study which, similarly to KIBRA,
displayed decreased expression levels in Prlr−/− mammary epi-
thelial cells, and are positively regulated by progesterone [9]. In
addition to Prlr itself, these genes included amphiregulin, cal-
citonin andWnt-4 [28–31]. Both prolactin and progesteronework
synergistically in driving alveolar morphogenesis. This has been
demonstrated in mammary cells where prolactin causes up-re-
gulation of the progesterone receptor, and conversely progester-
one up-regulates the prolactin receptor [28]. This may provide an
additional explanation for our detection of KIBRA as differen-
tially regulated in Prlr−/− epithelium compared to wild type.
We have shown here that KIBRA interacts with DDR1, a
collagen-activated receptor tyrosine kinase that is essential in
mammary gland development [27]. Similarly to KIBRA, DDR1
is epithelial-specific, shows an increase in expression in the
mouse mammary gland during pregnancy, and is also over ex-
pressed in several primary breast tumours [32]. Female DDR1
knockout mice show defects in blastocyst implantation together
with hyperproliferation and abnormal branching of the mammary
ducts which result in a lactational defect [27]. DDR1mutant mice
also show an increased amount of collagenous extracellular ma-
trix surrounding the mammary epithelium [27]. This observation
suggests a role for DDR1 in mediating extracellular matrix sig-
nalling within the mammary gland. The interaction between the
mammary epithelium and the extracellular matrix is essential for
complete alveolar morphogenesis and in the regulation of pro-
cesses such as cell motility and adhesion [33], which when
dysregulated can drive tumor progression by causing enhanced
migration, invasion or metastasis. A number of studies have
detected an overexpression of DDR1 in human tumours, par-
ticularly in primary breast cancer [32], and pediatric brain cancer
[34]. It has also been identified as a dysregulated gene in epithelial
ovarian cancer [35], and more recently as a novel marker for
differentiation of invasive ductal and lobular breast carcinomas
[36]. Since KIBRA binds DDR1 and regulates ERK MAPK
392 H.N. Hilton et al. / Biochimica et Biophysica Acta 1783 (2008) 383–393activation in response to the DDR1 ligand collagen, it will be
important to determine KIBRA expression in breast and other
cancers.
Our data demonstrate that the KIBRA-DDR1 complex dis-
sociates upon activation of DDR1 by collagen, suggesting a role
for KIBRA in the downstream signalling pathways induced by
the extracellular matrix. It is therefore interesting to note that
forced expression and activation of DDR1 with collagen in
mouse mammary epithelial HC11 cells resulted in increased
activation of Stat5, a downstream target of Prlr, as well as
increased β-casein gene expression [37]. This suggests that the
collagenous extracellular matrix and DDR1 signalling pathway
work in conjunction with the prolactin pathway in order to
maintain efficient lactogenesis. As KIBRA expression is regu-
lated by two hormones required for alveolar morphogenesis, we
postulate a role for the KIBRA-DDR1 interaction in integrating
hormone-stimulated and matrix-derived signals essential in
maintaining normal mammary gland function.
Other interacting proteins for both KIBRA and DDR1 have
previously been identified. KIBRA has been reported to be a
novel substrate for protein kinase Cζ (PKCζ) [14], a member of
the family of atypical PKCs, which are characterised by the
presence of only one zinc finger module, and do not bind or
respond to phorbol esters and diacylglycerol [38]. PKCζ is
important in regulating many cell processes, such as prolifera-
tion and differentiation, and when stably over expressed in a
murine mammary epithelial cell line has been shown to modu-
late cell proliferation, adhesion and migration, via activation of
the ERK MAPK pathway [39]. PKC isozymes have long been
implicated in carcinogenesis, and specifically, PKCζ shows
increasing expression correlating with increasing tumor grade in
urinary bladder cancer [40], is involved in cancer cell motility in
pancreatic adenocarcinoma cells [41], and has been shown to be
overexpressed in breast carcinomas [42]. With respect to DDR1,
other interacting proteins have previously been identified which
bind this receptor in a phosphotyrosine-dependent manner. One
study reported an interaction between the neuronal phospho-
protein DARPP-32 and DDR1, which similarly to KIBRA was
shown to be stronger in the absence of collagen, and their
interaction was shown to inhibit the migration of human breast
cancer cells [43]. In contrast, previous studies determined that
several other cytoplasmic signalling proteins, including Shc,
Nck2 and Shp-2, bind DDR1 but only following activation by
collagen [26,44].
In addition to the PKCζ pathway, ERK MAPK has also
previously been shown to be a downstream effector in the DDR1
pathway [45,46], and so our data demonstrating an interaction
between KIBRA, PKCζ and DDR1 in a complex, suggests a
potential role for KIBRA in activation of the ERK MAPK cas-
cade. This is further supported by our data showing that over-
expression of KIBRA in the presence of collagen causes an
increase in ERK phosphorylation, and conversely that knock-
down ofKIBRA expression inhibits ERKMAPK activation upon
collagen treatment. It is interesting to note that while unstimulated
DDR1has been shown to suppress ERKMAPKphosphorylation,
collagen-stimulated DDR1 induces ERK MAPK activation [45].
As collagen treatment is also required for ERK phosphorylationwhen KIBRA is over-expressed, and collagen inhibits the
KIBRA-DDR1 interaction, we propose a model whereby these
proteinsmust dissociate in order for activation of the ERKMAPK
cascade to occur, and that unstimulated DDR1 potentially inter-
acts with KIBRA to suppress ERK signalling. One possibility of
how this activation occurs is either via downstream signalling by
the KIBRA–PKCζ complex, or by KIBRA dissociation allowing
access to the collagen-activated receptor for molecules that
participate in Ras/ERK signalling, such as Shc. These models are
not mutually exclusive. It has previously been reported that
progestins can stimulate proliferation of mammary epithelial cells
derived from adult virgin mice in the presence of collagen type IV
[47]. One might speculate that this proliferation is a result of
activation of the ERK MAPK cascade due to an up-regulation of
KIBRA expression by progestin, in the presence of collagen. And
so from the data presented, we hypothesise that in cells which are
in contact with the extracellular matrix, modulation of KIBRA
expression by progesterone and prolactin is important in acti-
vating the ERKMAPK cascade required for tissue remodelling of
the mammary gland throughout its cycle of development.
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